Status: Recruiting
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 6-50Biological sex: AllType: InterventionalSponsor: HuidaGene Therapeutics Co., Ltd.Updated: Sep 19, 2024Locations: 3
Eligibility criteria
Male or females between 6 and 50 years of age at the time of signing the informe... [+5]
Pre-existing eye conditions that would preclude the planned surgery or interfere... [+6]